CDSCO approves German pharma firms drug to help reduce cardiovascular deaths in India

Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease. Jardiance or Empagliflozin is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease. The drug will reduce the risk of cardiovascular death plus hospitalisation for heart failure in adults with heart failure and reduced ejection fraction (HFrEF), the company said in a statement. HFrEF, which accounts for more than half of heart failure cases, occurs when the heart muscle does not contract effectively and less blood is pumped out to the body than a normally functioning heart. Jardiance received approval from the US Food and Drug Administration (FDA) earlier this year in August for the heart failure indication. This new indication approval applies to eligible patients with HFrEF, regardless of their type-II diabetes status, and is an addition to the previously-approved indications for glycemic control in type-II diabetes, as well established cardiovascular disease, the company said.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!